Eli Lilly CDR (CAD Hedged)
- Country
- đşđ¸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- Conditions
- HypertensionOverweight or Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 487
- Registration Number
- NCT06948435
- Locations
- đşđ¸
Dallas Heart and Vascular Consultants, PA, Duncanville, Texas, United States
đşđ¸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
đşđ¸Valley Clinical Trials, Inc., Northridge, California, United States
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
- Conditions
- HealthyOverweightType 2 DiabetesObesity
- Interventions
- Drug: LY4086940Drug: Placebo
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT06945419
- Locations
- đşđ¸
Fortrea Clinical Research Unit, Dallas, Texas, United States
đşđ¸Endeavor Clinical Trials, San Antonio, Texas, United States
đ¸đŹLilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
- Conditions
- HealthyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: LY4057996 SCDrug: Placebo SCDrug: Degludec SCDrug: LY4057996 IVDrug: Placebo IVDrug: Lispro SCDrug: Degludec IVDrug: Pre-study basal insulin SC
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT06945406
- Locations
- đŠđŞ
Profil Institut fĂźr Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Conditions
- Crohn's DiseaseObesity or Overweight
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 290
- Registration Number
- NCT06937099
- Locations
- đşđ¸
Digestive Health Specialists, Dothan, Alabama, United States
đşđ¸California Medical Research Associates, Northridge, California, United States
đşđ¸Research Associates of South Florida - Miami - Southwest 8th Street, Miami, Florida, United States
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Conditions
- Ulcerative ColitisObesity or Overweight
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06937086
- Locations
- đşđ¸
Digestive Health Specialists, Dothan, Alabama, United States
đşđ¸California Medical Research Associates, Northridge, California, United States
đşđ¸Research Associates of South Florida - Miami - Southwest 8th Street, Miami, Florida, United States
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 88
- Registration Number
- NCT06937411
- Locations
- đŹđ§
The Medicines Evaluation Unit Ltd., Manchester, United Kingdom
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
- Conditions
- Atopic Hand and Foot Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 206
- Registration Number
- NCT06921759
- Locations
- đşđ¸
Medical Dermatology Specialists, Phoenix, Arizona, United States
đşđ¸First OC Dermatology Research Inc, Fountain Valley, California, United States
đşđ¸Dermatology Research Associates, Los Angeles, California, United States
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06916091
- Locations
- đ¸đŹ
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- Conditions
- OverweightObesity
- Interventions
- Drug: Eloralintide and Tirzepatide
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 188
- Registration Number
- NCT06916065
- Locations
- đşđ¸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
đşđ¸Fortrea Clinical Research Unit, Dallas, Texas, United States
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT06916143
- Locations
- đşđ¸
Clinical Pharmacology of Miami, Miami, Florida, United States
đşđ¸Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States